SCM
PETX

Stevens Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Stevens Capital Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-14,634
Closed -$137K – 1202
2016
Q3 		$137K Buy
+14,634
New +$122K 0.01% 829

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stevens Capital Management's PETX Position: Q4 2016 in Review

Stevens Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2016, closing a stake of 14,634 shares — an estimated $137K sold.

Stevens Capital Management first reported a position in PETX in Q3 2016 and held it in 1 quarter. The position peaked at $137K in Q3 2016. 107 funds tracked by Wall St. Rank hold PETX as of Q4 2016.

  • Stevens Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Stevens Capital Management sold 14,634 Aratana Therapeutics, Inc. shares in Q4 2016, an estimated $137K.
  • Stevens Capital Management first reported a position in Aratana Therapeutics, Inc. in Q3 2016 and held it in 1 quarter.
  • Stevens Capital Management's Aratana Therapeutics, Inc. position peaked at $137K in Q3 2016.
  • 107 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2016.

Based on Stevens Capital Management's 13F filing for Q4 2016, filed 7 Feb 2017.